SynBioBeta Speaker

Jerry McLaughlin

Life Biosciences

CEO

Jerry McLaughlin is chief executive officer and director for Life Biosciences, a clinical-stage biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging. He has more than 30 years of biopharmaceutical experience, spanning drug discovery, clinical development, and global commercialization. Jerry has contributed to the approval and launch of more than a dozen FDA-approved medicines and has led multiple exits. Most recently, he served as President and CEO of Neos Therapeutics. Previously, he was president and CEO of AgeneBio, a clinical-stage biopharma focused on neurological and psychiatric diseases. He also served in senior management roles at NuPathe, Endo, and Merck & Co. Inc.

Sessions Featuring

Jerry

This Year

Fireside Chat

โ€ข

8:30 AM

-

9:00 AM

Longevity

Reprogramming Life: A Conversation on Longevity, Epigenetics, and the Future of Medicine

In this fireside chat, the panelists will explore the bold vision behind Life Biosciences and the rapidly advancing science of epigenetic reprogramming. From redefining aging as a reversible process to translating breakthrough research into the clinic, including the recently FDA-approved ER-100 trial. This conversation will unpack what it takes to turn longevity science into real-world therapies and discuss ways to slow biological aging. Join us for a forward-looking discussion at the intersection of biology, technology, and human healthspan.

Featuring

David Sinclair

Harvard Medical School

Professor, Genetics

TIME's 100, longevity pioneer building epigenetic-reset therapies

Jerry McLaughlin

Life Biosciences

CEO

Serena Poon

Fully Aligned Co.

Co-Founder

Fireside Chat

โ€ข

8:30 AM

-

9:00 AM

Longevity

Reprogramming Life: A Conversation on Longevity, Epigenetics, and the Future of Medicine

In this fireside chat, the panelists will explore the bold vision behind Life Biosciences and the rapidly advancing science of epigenetic reprogramming. From redefining aging as a reversible process to translating breakthrough research into the clinic, including the recently FDA-approved ER-100 trial. This conversation will unpack what it takes to turn longevity science into real-world therapies and discuss ways to slow biological aging. Join us for a forward-looking discussion at the intersection of biology, technology, and human healthspan.

Featuring

David Sinclair

Harvard Medical School

Professor, Genetics

TIME's 100, longevity pioneer building epigenetic-reset therapies

Jerry McLaughlin

Life Biosciences

CEO

Serena Poon

Fully Aligned Co.

Co-Founder

Previous Speakers Include